Compare Kroger Co (KR) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Tango Therapeutics Inc. — how do they compare? Kroger Co trades at $63.42 (market cap $35.87B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Kroger Co is far larger — about 9.6× Tango Therapeutics Inc.'s market cap, and Kroger Co pays a 2.57% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 109 Days and Tango Therapeutics Inc. for 0 Days on average.
| KR | TNGX | |
|---|---|---|
Market Cap | $35.87B | $3.75B |
Volume | 8,902,665 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $32.90 |
52-Week Low | $55.53 | $7.50 |
Typical Hold Time | 109 Days | 0 Days |
Enterprise Value | $57.29B | $2.77B |
Dividend Yield | 2.57% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $63.09, up 0.85% today, with a bullish technical signal and strong analyst consensus. The stock shows robust fundamentals with a low P/S of 0.26 and positive cash flow trends, though net income margin is thin at 0.73%. Recent news highlights digital growth and a strategic shift toward everyday low prices, while earnings have mostly beaten expectations.
Outlook is cautiously optimistic with a $70.62 consensus price target, but risks include integration challenges from acquisitions and cost pressures. The stock offers value with a dividend yield, yet investors should weigh slower sales guidance against operational improvements for near-term performance.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
